Proton beam radiotherapy of uveal melanoma.
Proton beam radiotherapy of uveal melanoma can be administered as primary treatment, as salvage therapy for recurrent tumor, and as neoadjuvant therapy prior to surgical resection. The physical properties of proton beams make it possible to deliver high-doses of radiation to the tumor with relative sparing of adjacent tissues. This form of therapy is effective for a wider range of uveal melanoma than any other modality, providing exceptionally-high rates of local tumor control. This is particularly the case with diffuse iris melanomas, many of which are unresectable. The chances of survival, ocular conservation, visual preservation and avoidance of iatrogenic morbidity depend greatly on the tumor size, location and extent. When treating any side-effects and/or complications, it is helpful to consider whether these are the result of collateral damage or persistence of the irradiated tumor ('toxic tumor syndrome').
Ocular Oncology Service, Departments of Ophthalmology and Radiation Oncology, University of California, San Francisco, United States ; Ocular Oncology Service, Royal Liverpool University Hospital, United Kingdom ; Douglas Cyclotron Unit, Clatterbridge Cancer Centre, United Kingdom.
Bertil
B
Damato
Andrzej
A
Kacperek
Doug
D
Errington
Heinrich
H
Heimann
Mortality; Neoadjuvant therapy; Proton beam radiotherapy; Recurrent tumor; Uveal melanoma